Jardiance (Empagliflozin) 25 mg 30 Film-Coated Tablets is a branded SGLT‑2 inhibitor used to improve blood glucose control in adults (and children aged 10+) with type 2 diabetes. It also reduces the risk of cardiovascular death, hospitalization for heart failure, and progression of chronic kidney disease.
Key Benefits of Jardiance (Empagliflozin) 25 mg 30 Film-Coated Tablets:
- Lowers HbA1c by ~0.7–0.8% and fasting glucose by ~19–25 mg/dL.
- Promotes moderate weight loss (~2–3%) and reduces systolic blood pressure by 3–5 mmHg.
- Provides cardiovascular and renal protection independently of glycemic control.
Mechanism of Action:
Blocks renal SGLT‑2, reducing glucose reabsorption and increasing urinary glucose excretion leading to lower blood sugar and mild diuresis.
Dosage & Administration:
- Typical dose: 1 tablet (25 mg) once daily in the morning, with or without food.
- Initial dose: Often starts at 10 mg, can be uptitrated to 25 mg for better glycemic control.
- Missed dose: Skip if near your next scheduled dose; do not double dose.
Warnings & Contraindications:
- Not for type 1 diabetes, diabetic ketoacidosis, or eGFR < 30 mL/min/1.73 m².
- Risk of dehydration, hypotension, and genital yeast infections.
- Serious but rare: euglycemic ketoacidosis, Fournier’s gangrene, acute kidney injury.
Common Side Effects:
- Genital mycotic infections, UTIs, increased urination, mild hypotension, thirst, nausea, headache.
Serious Side Effects:
- Euglycemic ketoacidosis (nausea, vomiting, stomach pain, breathing changes).
- Fournier’s gangrene, acute kidney injury, significant hypotension/hyponatremia.
Warnings & Patient Advice:
Ensure adequate hydration, monitor blood pressure and kidney function. Discontinue 3 days before surgeries or if unwell. Avoid in pregnancy and breastfeeding without medical guidance
Prescription Medication, SGLT‑2 Inhibitor, Antidiabetic, Empagliflozin, Type 2 Diabetes, Heart Failure, Renal Protection
